explore -WSS

explore

author：knowledge 2025-09-28 13:26:13 - browse：7

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Ozempic has benefits for kidney disease as well as diabetes

entertainment

hotspot

WSS

Microsoft's Peter Lee: Generative AI could help doctors be more human

Longer MASH drug regimen improved liver, Akero study finds

3 hurdles to bringing medical devices to the U.S. market

A new approach to psychiatric drug development

Death of patient in Alzheimer’s trial raises question of possible risks

Ask STAT: What do you want to know about ChatGPT in medicine?

hotspot

explore

entertainment

How one medical school became remarkably diverse

In areas with more Black doctors, Black people live longer

Medical records are filled with copy

Pregnant women don't need prenatal multivitamins, study concludes

Virginia high school admissions case could be legal follow

Fetal cell organoids grown from amniotic fluid, study finds

Dobbs anniversary: the lost opportunity of abortion as health care

The story of mRNA: From a loose idea to a tool that may help curb Covid

Novavax promises a turnaround & Lilly roils the obesity market

New guidelines on severe brain injury complicate already difficult decisions

focus

Death of patient in Alzheimer’s trial raises question of possible risks

Stem cell biologist probes earliest stages of human development

Gene therapy has helped boys walk. Can scientists keep it that way?

Lack of health data on LGBTQ+ people has serious consequences

Paxlovid study fails to answer questions over benefit for broader groups

$1 billion proposal to grow Boston, Massachusetts biotech

entertainment

focus

hotspot

focus